(Total Views: 385)
Posted On: 07/10/2020 2:45:38 PM
Post# of 72
Cont'd from Chris:
"In the second chart, we have developed a proposed treatment algorithm following FDA approval, as a new anti- anginal with a mechanism of action, as a angiogenic gene therapy. Generx is single administration , angiogenic gene therapy which is administered during a basic diagnostic angiogram procedure by a interventional cardiologist for a patients with refractory angina. To be eligible for the Ad5FGF-4, a patient will have failed anti-angina drug therapy, and not be eligible for mechanical revascularization (bypass surgery or stent). As this chart further details, we estimate there is an estimate that are approximately 1.2 million patients in the US with refractory angina. It is an significant unmet, medial need, which was the basis for the Generx product candidate being designated with FDA Fast Track status. It is our focus is to offer patients with chronic myocardial ischemia with a new therapeutic clsdd whice we are poneering called “medical revascularization” ( our angogenic therapy) , in addition only two current treatment options: (1) maximal anti-anginal drugs and (2) mechanical revascularization."
"In the second chart, we have developed a proposed treatment algorithm following FDA approval, as a new anti- anginal with a mechanism of action, as a angiogenic gene therapy. Generx is single administration , angiogenic gene therapy which is administered during a basic diagnostic angiogram procedure by a interventional cardiologist for a patients with refractory angina. To be eligible for the Ad5FGF-4, a patient will have failed anti-angina drug therapy, and not be eligible for mechanical revascularization (bypass surgery or stent). As this chart further details, we estimate there is an estimate that are approximately 1.2 million patients in the US with refractory angina. It is an significant unmet, medial need, which was the basis for the Generx product candidate being designated with FDA Fast Track status. It is our focus is to offer patients with chronic myocardial ischemia with a new therapeutic clsdd whice we are poneering called “medical revascularization” ( our angogenic therapy) , in addition only two current treatment options: (1) maximal anti-anginal drugs and (2) mechanical revascularization."
(0)
(0)
